Roble, Belko & Company, Inc Seagen Inc. Transaction History
Roble, Belko & Company, Inc
- $583 Million
- Q1 2024
Shares
1 transactions
Others Institutions Holding SGEN
# of Institutions
40Shares Held
1.26MCall Options Held
23KPut Options Held
55.2K-
Pictet Asset Management Sa Geneva 73, V8802KShares$00.19% of portfolio
-
Berry Street Capital Management LLP London, X0206KShares$012.86% of portfolio
-
Tekla Capital Management LLC112KShares$00.86% of portfolio
-
Eaton Vance Management Boston, MA51.3KShares$00.01% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC23KShares$02.7% of portfolio
About Seagen Inc.
- Ticker SGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,664,992
- Description
- Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...